Arundhati Parmar is the Editor-in-Chief at MedCity News. She focuses on healthcare and innovation, covering themes such as health and wellness, medicine, diagnostics, and the intersection of technology and healthcare, including topics like AI and startups. Arundhati is featured in MedCity News.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Not enough data
Arundhati Parmar's articles primarily revolve around the healthcare and pharmaceutical industry, with a focus on expert commentary, government announcements, and press releases. Given her coverage attributes, she may be particularly interested in pitches featuring insights from experts within the healthcare or pharmaceutical sectors.
Pitches that align with Arundhati's coverage could include topics related to digital health innovations, challenges faced by the healthcare industry, business strategies within healthcare organizations, and regulatory developments impacting healthcare providers and patients.
Considering her lack of specified geographic focus but evident interest in broad industry trends and impacts across regions (e.g., New York state laws), relevant topics should appeal to an international audience while focusing on key developments in global healthcare.
This information evolves through artificial intelligence and human feedback. Improve this profile .
I met a mix of biotech and healthtech companies at HLTH affecting everything from drug development, drug efficacy to controlling specialty care costs and managing chronic diseases.
By: Arundhati Parmar
In an interview, Rabah talked about the promise of AI, where it can have the most impact, while also responding to the IRA and high drug prices in the United States.
The Glp-1 battle heats with new preliminary data from Eli Lilly showing that patients using its weight loss drug Zepbound lost more weight on average in 72 weeks than those on Novo Nordisk's Wegovy.
By: Arundhati Parmar
Dr. Maria Pulido, chief medical officer, of Ascension St. Vincents, explains why he believes tools like Wellsheet makes the hospital care team's job so much easier.
By: Arundhati
Swiss Medtech Company Medacta teamed up with Geisinger to begin providing the world's first, lifetime guarantee on shoulder replacement surgeries.
By: Arundhati Parmar, Marissa Plescia
Transcarent is planning to acquire Accolade for $621 million, the companies announced Wednesday. The two companies are very complementary and the deal gives Accolade a chance to turn things around after struggling in the public market, experts say.
In a sit-down interview at the annual J.P. Morgan Healthcare conference, Allen talked about a tool built by a company backed by General Catalyst and Andreessen Horowitz.
More than a decade ago, Medtronic announced that a pivotal trial testing its renal denervation system had failed. Though it got approved later, reimbursement has been elusive. All that might change this year.
By: Arundhati Parmar
Albert Bourla and other healthcare CEOs talked about the efficacy of vaccines and how public health could take a big turn for the worse if the incoming Trump administration veered away from accepted norms regarding vaccines.
Thomas Senderovitz, senior vice president of data science at Novo Nordisk challenges conventional notions about AI and the need for humans in the loop.
(833) 317-6278 
